key: cord-1033727-1b3cyl0w authors: Greenberg, Stephen B. title: Update on Human Rhinovirus and Coronavirus Infections date: 2016-08-03 journal: Semin Respir Crit Care Med DOI: 10.1055/s-0036-1584797 sha: cc61669b101c17442d109c49830f34c49aace5c1 doc_id: 1033727 cord_uid: 1b3cyl0w Human rhinovirus (HRV) and coronavirus (HCoV) infections are associated with both upper respiratory tract illness (“the common cold”) and lower respiratory tract illness (pneumonia). New species of HRVs and HCoVs have been diagnosed in the past decade. More sensitive diagnostic tests such as reverse transcription-polymerase chain reaction have expanded our understanding of the role these viruses play in both immunocompetent and immunosuppressed hosts. Recent identification of severe acute respiratory syndrome and Middle East respiratory syndrome viruses causing serious respiratory illnesses has led to renewed efforts for vaccine development. The role these viruses play in patients with chronic lung disease such as asthma makes the search for antiviral agents of increased importance. More than 50% of all common colds are caused by human rhinoviruses (HRVs) and coronaviruses (HCoVs). [1] [2] [3] The common cold includes rhinitis and pharyngitis, as well as sneezing, hoarseness, and cough. 4, 5 The illness is usually selflimited in healthy people, but can be associated with complications in individuals who suffer from heart or lung disease, or who are immunosuppressed. 6-11 As a frequent cause of the common cold, these viruses are responsible for millions of lost work days, school absenteeism, and physician visits. In infants and young children, these viruses are associated with many cases of acute otitis media (AOM) and rhinosinusitis. 12 Newer more sensitive diagnostic tests have increased the percentage of respiratory illnesses attributable to these viruses. [13] [14] [15] Most HRV infections are symptomatic, but asymptomatic virus shedding has been reported with increasing frequency. In the past 10 years, several new HRVs and HCoVs have been identified. [16] [17] [18] In addition, recent studies have provided a better understanding of the pathogenesis of these viral infections which could lead to more specific treatments. This review will update recent advances in our knowledge of these two virus groups and their importance in respiratory viral infections. HRVs are positive-sense, single-stranded ribonucleic acid (RNA) viruses with icosahedral symmetry. The capsid is composed of four proteins: VP1, VP2, VP3, and VP4. 4, 19 VP4 is on the inside of the virus and anchors the RNA core to the viral capsid. The complete sequencing of all known HRV genomes has been reported. 20 More than 150 serotypes of HRVs have been identified. Most of the HRV serotypes of the HRV-A and HRV-B families use intercellular adhesion molecule-1 (ICAM-1; major group) as the cell receptor for the virus entry. A few HRVs used heparin sulfate proteoglycan as an additional receptor and approximately 10 serotypes use low-density lipoprotein as the cell receptor (minor group). In 2002, a new clade of HRVs was reported and labeled HRV-C. 19 Although HRV-C strains have been characterized by genome sequencing, the receptor used to infect epithelial cells is currently unidentified. During replication, the RNA genome serves as an mRNA, which encodes the capsid or structural proteins, as well as the nonstructural proteins. 4 After cell entry, the viral genome is translated into a polyprotein, which undergoes proteolytic cleavage to produce the structural and nonstructural gene Keywords ► human rhinovirus ► human coronavirus ► polymerase chain reaction Human rhinovirus (HRV) and coronavirus (HCoV) infections are associated with both upper respiratory tract illness ("the common cold") and lower respiratory tract illness (pneumonia). New species of HRVs and HCoVs have been diagnosed in the past decade. More sensitive diagnostic tests such as reverse transcription-polymerase chain reaction have expanded our understanding of the role these viruses play in both immunocompetent and immunosuppressed hosts. Recent identification of severe acute respiratory syndrome and Middle East respiratory syndrome viruses causing serious respiratory illnesses has led to renewed efforts for vaccine development. The role these viruses play in patients with chronic lung disease such as asthma makes the search for antiviral agents of increased importance. products. Serotypes of HRVs are based on amino acid differences in the four capsid proteins. Enteroviruses (EVs) are not typically thought of as causing acute respiratory tract infections. However, EV68 has properties of both EVs and HRVs, and has been independently identified as HRV serotype 87. 21 EV68 and EV104 have been associated with respiratory illness in multiple countries. [22] [23] [24] [25] [26] Pathogenesis HRV infections initially involve the upper respiratory tract. After deposition of HRV in the eye or nose, the virus attaches to host cell epithelium. Infection of nasal epithelial cells results in increased neutrophils detectable in the nasal mucosa and secretions with release of inflammatory mediators. Although HRVs replicate best at 33°C, they have been found in lower respiratory tract cells where the temperature is 37°C. HRVS do not produce cytopathologic changes; however, HRVs appear to disrupt tight junctions between cells, leading to increased vascular leakage and mucus secretion. Using primary nasal epithelial cells, HRV was found to alter the function and the expression of cystic fibrosis transmembrane conductance regulator (CFTR), α-epithelial sodium channel (α-ENaC), β-epithelial sodium channel (β-ENaC), and γ-epithelial sodium channel (γ-ENaC). 27 These findings may help explain the mechanism by which altered mucociliary clearance is associated with HRV infections. Most of the symptoms following HRV infection can be ascribed to the host response to the virus, including those mediated by the innate, mucosal, and cellular immune systems. Following epithelial cell attachment and internalization, HRV infection results in cytokine expression, including type I and type III interferons (IFNs), interleukin (IL)-6, IL-11, IL-12, IL-15, and IL-1B. 28-32 Neutrophil recruitment results from release of growth factors and chemokines. VP-I binds to ICAM-1 and is the major target for the memory immune response, residing in IgG1 subclass and IgA class antibodies. The majority of VP-1-specific antibodies are directed against an N-terminal 20-mer peptide (Pla), which is located inside the capsid. The antibody response to HRV in humans appears to be misdirected against a nonneutralizing epitope that is exposed during uncoating. In a group of children with asthma and upper respiratory infections (URIs), type III IFN-λ levels were significantly higher in wheezing children infected with HRV compared with non-wheezing children. 33 Although type III IFN-λ levels were lower at baseline in children with asthma compared with healthy children, they were found to be hyperexpressed during asthma exacerbation. In addition, a study reported that IFN-λ has antiviral and anti-inflammatory properties in primary epithelial cells from asthmatic patients exposed to rhinovirus. 34 In a recently published mouse model of HRV infection, adult mice had an enhanced type 2 immune response and attenuated type 1 response compared with neonatal mice. 35 The authors reported long-term mucosal metaplasia and airway responsiveness in HRV-infected neonatal mice. In addition, they found increased expression of epithelial IL-25 with neonatal rhinovirus infection. IL-25 appears to mediate metaplasia and airway hyper-responsiveness in the HRV-infected neonatal mice. Induction of type 1 cytokines, IFN-γ, IL-12p40, and tumor necrosis factor-α was diminished in neonates compared with adult mice. HRV infection elicits an increased ILC2 response in neonatal mice. These observations may help our understanding of the intersection of early HRV infections and subsequent development of asthma. HRVs cause respiratory illnesses throughout the world, in all age groups, and throughout the year, although most prevalent in the fall and spring in temperate climates. 36 In one study, HRVs accounted for approximately 50% of common colds. 37 HRVs commonly infect children in early childhood and into adulthood. School-aged children frequently introduce HRV infections into the home. Secondary attack rates range from 25 to 70%. Day-care centers and schools are also important locations for the spread of HRV. HRV transmission can occur by close contact, autoinoculation, fomites, or aerosols. Clinical outcomes appear to be similar between the HRV species. The recently identified HRV-C infections can have symptoms of the common cold, pharyngitis, croup, AOM, bronchiolitis, and/or pneumonia. 38-40 These infections have been reported in healthy children and adults, as well as in those with asthma, immunocompromised conditions, CF, or multiple sclerosis. 41- 45 HRV-Cs, more than HRV-As and -Bs, are major causes of wheezing in infants and of asthma exacerbations in older children. 46 Of all viruses detected from middle ear fluids in children with otitis media, HRV-Cs accounted for half of the documented infections. 47 Although reported infections have come mainly from respiratory tract specimens, HRV-Cs have been rarely reported in blood and pericardium. 48, 49 With more sensitive polymerase chain reaction (PCR) methods for HRV detection, several reports of long periods (>2-3 weeks) of HRV positivity have been published. 50, 51 Where strain typing has been used, however, HRV shedding normally stops within 11 to 21 days. Therefore, persistence may represent serial or overlapping infections by multiple untyped strains. 52 In immunocompromised children, HRV-C strains were detected threefold longer (53 vs. 16 days) than in immunocompetent children. 53 Recent studies have documented HRV species in all months of the year in tropical, subtropical, and semi-arid regions. 54, 55 Many HRV-C strains have been found to circulate during a single year and may be detected in subsequent years. 56 Standard tissue culture methods for isolation are useful for detecting HRV infection but are not very sensitive. With the development of PCR techniques, the ability to detect respiratory viruses has increased significantly. Detection of HRVs in respiratory specimens was enhanced by reverse transcription-PCR (RT-PCR), involving the use of hybridization probes or double-stranded DNA binding dye. Several studies have found an increased sensitivity of RT-PCR compared with viral culture techniques. [57] [58] [59] [60] [61] Antibody assays are reported for HRVs, but are not readily available or helpful clinically. Since there is no common antigen for HRVs, serotype-specific neutralizing antibody assays are necessary to detect rises in serum antibodies following acute infections, but the large number of HRV serotypes makes this approach impractical. The incubation period for the common cold is 12 to 72 hours. Rhinorrhea and sneezing plus nasal congestion are usually the initial symptoms. 62, 63 Sore throat is common and may be an early symptom. Fever is unusual. Headache and malaise are often mild. Resolution of symptoms occurs in almost all cases within 4 to 9 days. With the use of PCR techniques, HRVs have been reported commonly in asymptomatic children. 3 This may be a result of prolonged shedding from a previous respiratory illness, a mild illness that went unrecognized, or a new virus infection during the incubation period. Asymptomatic HRV shedding is not as common in adults as it appears to be in children. In addition, coinfections with other respiratory viruses during respiratory illnesses are well described. [64] [65] [66] [67] [68] [69] [70] [71] With the global spread of influenza A (H1N1) in 2009, a series of surveillance protocols were activated to monitor and characterize the pandemic. Many countries have reported on their findings in patients with influenza-like illnesses (ILI) who had respiratory specimens tested for a wide range of respiratory viruses. Most of the reports used PCR techniques in children or adults (►Table 1). 70, [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] The percentage of specimens that were positive with HRV ranged from 6.3 to 40.6%. In all the studies, the influenza illnesses could not be distinguished from HRV-related illnesses by clinical characteristics. During influenza outbreaks, other respiratory viruses, and especially HRV, continue to cause significant cases of URIs and lower respiratory infections (LRIs). Asthma exacerbations in children and adults are frequently associated with respiratory virus infections, especially HRVs. [87] [88] [89] [90] HRV infections lead to more severe and longerlasting lower respiratory tract symptoms. 90 Lower airway dysfunction following HRV infection may result from direct infection of the lower airway or by stimulating inflammatory, immunologic, or neurogenic mechanisms in the upper airway, thereby impacting the lower airways. HRV has been detected in the columnar and basal cell layers of the lower airways. 91 Using in situ hybridization, the replicative strand of HRV in the lower airways has been detected. 92 Experimental HRV infections in asthmatic subjects have demonstrated airway narrowing, markers of eosinophil activation, bronchial infiltration with eosinophils, CD4 cells and CD8 cells, activation of prostaglandin and leukotriene pathways, and induction of nitric oxide. [93] [94] [95] Innate immune responses were found to be defective in bronchial epithelial cells obtained from asthmatic subjects. Impaired Th1 responses to HRV were found in peripheral blood mononuclear cells, as reflected by significantly lower levels of IFN-α and IL-12, and higher levels of IL-10 from asthmatic patients compared with normal healthy volunteers. 96 Several studies have found deficient induction of IFN-λ by HRV in bronchial epithelial cells from asthmatic patients. 97 Table1 Induction of IFN-λ1 and IFN-λ2/3 mRNAs was significantly reduced in asthmatic compared with nonasthmatic subjects. Bronchoalveolar cells in asthma patients were deficient in IFN-λ after HRV was added. These studies support the view that innate immune responses in asthmatic subjects have deficiencies in two IFN families, in several lung cell types, and in response to HRV infection. HRV infections are a major cause of wheezing episodes in infants and children. [98] [99] [100] Wheezing episodes in infancy that are virus induced are often associated with asthma development in children. HRV infections that resulted in hospitalization during infancy were recently implicated as early predictors of subsequent development of asthma. 101, 102 Almost 90% of wheezing children in year 3 of the study had asthma diagnosed by 6 years of age. Outpatient HRV wheezing illnesses during infancy were also found to be predictors of wheezing through 3 years of age. [103] [104] [105] [106] [107] The possible relationship between HRV wheezing illness and genetic risk of childhood-onset asthma was studied in a group of prospectively studied children. 108 The participants were children who had been studied since birth and cultured for HRV. In children who had HRV wheezing illnesses, there was significant association with 17q21 gene locus. Multiple longitudinal studies have documented the importance of respiratory viral infections in acute exacerbations of chronic obstructive pulmonary disease (COPD). [109] [110] [111] [112] [113] Other studies, using PCR techniques for respiratory virus detection, have found that more than 40% of COPD exacerbations are associated with respiratory viruses, especially HRVs. Inflammatory mediators, especially IL-8, have been found in increased levels of respiratory secretions obtained from stable COPD patients. Studies have demonstrated an increase in Staphylococcus aureus and Streptococcus pneumonia adherence to respiratory epithelial cells infected with HRV. In an in vitro study using primary differentiated human cell culture lines, a strain of nontypeable Haemophilus influenza was found to potentiate airway epithelial cell responses to HRV by increasing ICAM-1 and Toll-like receptor-3 expression. 114 However, it is unclear whether the interaction of respiratory virus with bacterial pathogens is a common cause of exacerbations of COPD or whether respiratory viruses, such as HRV, cause these pulmonary complications. Viruses, especially HRVs, result in an inflammatory reaction that results in mucociliary damage, impaired middle ear function, and increased mucus in the Eustachian tube. This leads to superinfection of the middle ear by bacteria and fluid accumulation (effusion). Recent studies detected HRVs in 40% of children with otitis media with effusion. [115] [116] [117] [118] HRVs were cultured in 24% of nasopharyngeal specimens. In a prospective study of 121 otitis-prone children, nasopharyngeal swabs were assayed by PCR for respiratory viruses and by culture for bacterial pathogens. HRVs were found at baseline in 30% of specimens. Positive PCR tests for HRV correlated with culturing Moraxella catarrhalis and S. pneumonia but not nontypeable H. influenzae. HRV and bacterial pathogens were found in otitis-prone children even in the absence of clinical symptoms. Most new otitis media episodes are coincident with a HRV URL. In a recently published study in South African children with AOM, 74.2% of cases had respiratory viruses detected from middle ear fluid specimens. 119 HRVs were detected in 37.7% of children with AOM. Respiratory viruses were recovered in 72% of episodes which had negative bacterial cultures. HIV status did not alter the spectrum of respiratory viruses recovered. Patients with the common cold syndrome have sinus abnormalities detectable by computed tomography. 120, 121 Abnormalities are most frequently detected in the maxillary and ethmoid sinuses, and resolve without antibiotics in 80% of patients followed over several weeks. Less than 20% of cases of viral rhinosinusitis are complicated by bacterial infection. 122 In a study of 20 adults with acute rhinosinusitis, 15% had virus cultures positive for HRV, but 50% were positive using RT-PCR on maxillary sinus aspirates or nasal swabs. 123 Intranasal pressure increases following nose blowing, sneezing, and coughing, and is high enough to propel virus-infected nasal reactions into the sinuses. 124 Multiple studies using PCR assays have shown that HRVs do cause community-acquired pneumonia (CAP) in both children and adults. [125] [126] [127] [128] Studies in children have reported a range of 0 to 52% positive specimens for HRV (►Table 2). [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] Bronchiolitis in children has been commonly reported in infants and young children. The most commonly reported virus recovered in acute cases has been RSV. As with CAP series, mixed infections with a second respiratory virus were common. In studies testing for respiratory viruses in adults with CAP, HRV was detected in 4 to 40% of cases (►Table 3). [149] [150] [151] [152] [153] [154] [155] As many cases of CAP had mixed infections, it is difficult to be certain if the HRV contributed to CAP. A few studies have examined the role of respiratory viral infections in CF patients. 156 Picornavirus was detected in more than 40% of URIs in children with underlying CF. 157 There was no difference in pulmonary function in those children with proven HRV infection versus other respiratory viruses. Smyth et al followed up 108 patients with CF for 1 year, and detected HRV in 16% of exacerbations. 158 Those patients with proven HRV infection did not show deterioration in clinical activity, but did receive more days of intravenous antibiotics. Goffard Respiratory virus infections are common causes of acute respiratory illness in patients after solid-organ transplantation or following bone marrow transplantation. [161] [162] [163] [164] [165] [166] In these immunocompromised patients, HRV was the number one detected respiratory virus by PCR assays. Ison et al found an 83% (5/6) fatality rate in hematopoietic stem cell transplantation patients with bronchoalveolar lavage (BAL)-posi-tive samples for HRV. 162 In a study of 215 patients with underlying HCT, 30% had infections at 100 days posttransplant. 166 The incidence for HRV was 22.3%. Median duration of virus shedding was 3 weeks. HRV infection was associated with URI symptoms. In a prospective study of patients with malignancies and neutropenia, a virus was detected in 35% of patients. 167 HRVs were the most common virus detected by quantitative PCR in nasopharyngeal aspirates. In a prospective, multicenter study in children with cancer and fever and neutropenia, 57% had a virus detected by PCR-DNA. A third of the patients had mixed 183 Clinical trials demonstrated significant reduction in duration of respiratory symptoms in individuals receiving pleconaril, but the drug has not been approved. Alternative medications, such as Echinacea angustifolia or zinc lozenges, have been tested in several volunteer trials but are not currently thought to be clinically effective. [184] [185] [186] [187] All of these studies suffer from inadequate control groups or incomplete virologic evaluation. Quinolones have been used to treat exacerbation of COPD because of their broad antibacterial spectrum and anti-inflammatory properties. Recently, levofloxacin has been found to inhibit HRV infection in primary cell cultures employing human tracheal epithelial cells. 188 Levofloxacin pretreatment decreased mRNA levels of ICAM-1. Macrolides have also been reported to reduce ICAM-1 expression and HRV-induced cytokines in vitro and in vivo. 189 A recent randomized controlled study evaluated the clinical benefit of oral prednisolone for treating a first episode of HRV-associated wheezing in young children younger than 23 months. 190 No long-term benefits were demonstrated in those children receiving oral prednisolone with their first HRV-associated wheezing episode. Short-term benefits were found in those receiving the oral prednisolone. This included less cough, rhinitis, and night-time respiratory symptoms. In a subset of children who had high viral loads (>7,000 copies/ mL), a long-term benefit of prednisolone therapy was detected. Future studies will have to confirm these findings before a general recommendation can be made for corticosteroid treatment in asthma-prone children with HRV-associated wheezing episodes. HRV can be recovered from the hands of approximately 40% of adults with colds. Hand-to-hand transmission of HRV has led to the evaluation of disinfectants that will eliminate virus on human skin. Trials to reduce hand transmission have reported differing results. 191, 192 A recently published study in Bangladesh demonstrated that nasal swab samples and paired hand rinse samples had HRV detected by rRT-PCR in 21 and 29% of samples, respectively. 193 A study using 2% of aqueous iodine decreased transmission in family members who were exposed to HRV-infected individuals. An evaluation of virucidal hand treatments confirmed the prevention of HRV infections by organic acids but not ethanol. 192 Hand washing with soap and water effectively cleans HRV-contaminated hands better than single treatment with ethanol hand rub. 192 Vaccines have not been thought to be useful against HRVs because of the serotype-specific neutralizing antibodies produced following infection and because of the numerous serotypes. [194] [195] [196] [197] However, recent studies in a mouse model have reported development of cross-serotype reactive antibodies to VP1, suggesting a basis for successful antibodymediated vaccine development. Future studies will need to confirm and expand these preliminary observations. Coronaviruses are positive, single-stranded RNA viruses that replicate in the cytoplasm and bud into cytoplasmic vesicles from the endoplasmic reticulum. Coronaviruses are divided into three groups: alpha, beta, and gamma. CD13 (human aminopeptidase N) is the cellular receptor for HCoV-229E (►Table 4). [198] [199] [200] Recent studies have shown that the newly reported HCoV-NL63 does not use CD13 as the receptor cell entry. HCoV-NL63, along with severe acute respiratory syndrome (SARS)-CoV, uses angiotensin-converting enzyme 2 (ACE2) as the entry receptor. 201 ACE2 is found on the ciliated nasal and tracheobronchial epithelial cells. The receptor for HCoV-OC43 is not known. Carcinoembryonic antigen (CEA) is the receptor for mouse hepatitis virus. 202 Phylogenetic relationships between coronaviruses have been based on deduced amino acid sequences of the coronavirus replicase, ORF1b gene. Middle East respiratory syndrome (MERS)-CoV belongs to the genus Betacoronavirus (BCoV) in the family Coronaviridae. 17 It is the first lineage C βCoV and the sixth coronavirus known to infect humans. MERS-CoV is an enveloped, positive-sense, single-stranded RNA virus. The replication cycle is similar to other CoVs. The host cell receptor for the MERS-CoV S protein is dipeptidyl peptidase-4 (DPP4) or CD26. This receptor is expressed on endothelial and epithelial cells of the kidney, lung, small intestine, liver, as well as on immune cells. This ability to infect many different organ cells may explain the extrapulmonary clinical characteristics in patients. After uncoating, there is translation of ORF/a/b, followed by transcription and genome replication. Following translation on the rough ER, budding and assembly of virions occur in the cytoplasm with exocytosis and virion release. ACE2 is a SARS-CoV receptor. Upon SARS-CoV infection, ACE2 expression in lungs is markedly downregulated and therefore helps explain SARS pathogenesis and progression to acute respiratory distress syndrome (►Table 5). Coronaviruses attach to cellular receptors by the spike proteins on their surface. 203, 204 Internalization into host cells occurs by direct fusion with the plasma membrane or by endocytosis. Posttranslational proteolytic processes are important regulatory mechanisms. Polyproteins are cleaved by viral proteases, facilitating assembly of subunit protein complexes that are responsible for replication and transcription. 205 There is little information on the host response to coronavirus replication. Humoral immune responses are detectable following natural infection, but the role of cellmediated immunity is largely unknown. 206, 207 There are several in vitro and in vivo differences between SARS-CoV and MERS-CoV infections. There are radiographic differences, as well as differences in cytopathic effect. The Coronaviruses were detected as agents of respiratory infections approximately 40 years ago. [210] [211] [212] They were later identified as coronaviruses, labeled "OC43" and "229E," and accepted as a new genus in 1975. In epidemiologic studies in adults, coronaviruses were estimated to cause 15% of adult common colds. Coronaviruses were found to cause epidemics every 2 to 3 years with reinfections being common. All ages are susceptible. From epidemiologic studies, coronaviruses were found to be associated with respiratory illnesses, usually in the upper respiratory tract, but occasionally causing pneumonia. In temperate climates, HCoV-OC43 and HCoV-229E are transmitted primarily during the winter. They have been linked to asthma and COPD exacerbations in children and adults. 125, 213 In 2004 and 2005, three closely related coronavirus species were reported. 214-219 NL63 was isolated from a 7-month-old girl with coryza, conjunctivitis, fever, and bronchiolitis. From epidemiologic studies, patients with HCoV-NL63 have ranged in age from 1 month to 100 years, with the highest infection rate occurring before age 5 years. Using molecular probes that targeted conserved regions of the coronavirus genome, a related coronavirus (HCoV-NH) was found in 79 of 895 young children tested by RT-PCR on respiratory specimens. In a prospective study in Hong Kong, coronaviruses were detected in 2.1% of patients admitted to the hospital with signs and symptoms of acute respiratory illness. 220 Of the 87 infected patients, 13 were positive for HCoV-HKU1, 17 were positive for HCoV-NL63, 53 were positive for HCoV-OC43, and 4 were positive for 229E. HCoV-HKU1 and HCoV-OC43 peak in the winter months. Upper respiratory tract illness was the most common presentation for HCoV-HKU1 infections. HCoV-NL63 infections occurred in early summer and fall but not in the winter. Using newer molecular assays, the group at Vanderbilt reassessed the role of the newly described coronaviruses in a large cohort of healthy children who had been followed up prospectively for 20 years. 221 Of the LRI samples available for screening, 8.4% had positive results for HCo-V and all were younger than 2 years. AOM was found in half of the HCo-Vinfected children, but none of the children were hospitalized. Of the URI samples tested, 4.7% had detectable HCo-V RNA. Fifty-one percent of these positive children were diagnosed with AOM. The burden of URI attributable to HCo-V had significant year-to-year variation. A recent study has provided evidence of genetic variability in OC43 strains. 222 The complete nucleotide sequence of two contemporary OC43 strains compared with the prototype strain (ATCC VR 759) demonstrated important amino acid substitutions in the potential cleavage site sequence of the spike protein. In 2002, the first cases of SARS were reported in Guangdong Province of China. 223 Over the next few months, 29 countries reported cases in more than 8,000 patients with approximately 10% fatalities. A patient who acquired SARS in Guangdong traveled to Hong Kong and is thought to be the index case for over half of the cases. It was different from known human and animal coronaviruses by DNA sequencing. This new coronavirus was cultured from Himalayan palm civets, but it is now thought that bats are the primary reservoir (►Fig. 1). SARS infected more than 8,000 people resulting in more than 700 deaths. MERS epidemiology originally implicated the dromedary camel as the source of human cases (►Fig. 1). 224, 225 Of the first 500 confirmed cases, 62% required hospitalization. Comorbid medical conditions were common and males were more likely to be identified as infected. The median age was 56 years. Secondary cases were commonly identified in younger health care workers. The incubation period was 5.2 days (range: 1.9-14.7 days). Mortality rates were reported to be approximately 35%. 226, 227 Coronaviruses require special cell lines or organ culture for detection by cultivation methods. 230 These cell or organ culture techniques are labor intensive, time consuming, and relatively insensitive. Coronaviruses have also been detected by RT-PCR with greater sensitivity than standard culture techniques. 231 SARS-CoV was initially detected by RT-PCR and culture. Viral RNA is found in high levels in the feces of SARS patients. To confirm SARS-CoV infection, the WHO criteria require detection of viral RNA by PCR, increase in antibody titers in body fluids, or isolation of SARS-CoV from clinical isolates. 232 Laboratory diagnostic methods for SARS-CoV include (1) viral RNA detection using RT-PCR, (2) immunofluoroscent antibody (IFA), and (3) ELISA. Virus isolation is less sensitive than these other methods and requires a biosafety level 3 (BSL-3) facility. Antibody assays are reported for coronaviruses, but are not readily available or helpful clinically. Complement-fixing and ELISA antibody assays for coronaviruses 229E and OC43 have been published, but are not available in clinical laboratories. 233,234 Therefore, serologic tests for antibody-specific responses are mainly reserved for research or epidemiologic studies. Serological assays are a complement to nucleic acid detection assays for SARS-CoV and MERS-CoV. [235] [236] [237] They have been helpful in identifying the source of the infection, in transmission pattern analysis, patient contact studies, and diagnosing asymptomatic cases. Even with the number of assays available after the SARS and MERS outbreak, differentiating HCoVs by serologic means remains a problem. Viral neutralization tests remain the most specific assay available, but are limited to only a few laboratories. Animal virologic data from surveillance studies support the theory that MERS originated from bats in Africa and crossed species barriers to infect camels many years ago. Infected camels were then transported to the Middle East where they transmitted MERS-CoV to humans. A recent report showed through complete genome sequencing that a virus isolated from a dromedary camel was identical to a human strain isolated from sick humans who had developed MERS following close contact with sick camels. 238 The mode of transmission from camels to humans is currently unknown, although droplet transmission seems likely. Laboratory confirmation of MERS required nucleic acid amplification assays. The WHO criteria for confirmed cases includes (1) þ RT-PCR for two different specific targets or (2) þRT-PCR from one specific target plus an additional different RT-PCR product sequenced and confirmed as MERS-CoV. A BSL3 is required for viral culture and neutralizing antibody detection assays. In a prospective study of respiratory viral infections among hospitalized patients, 5.7% had coronaviruses identified. 220 The 47 coronavirus infections represent 10.5% of all the respiratory viral infections. In 14 patients, coronaviruses were associated with another respiratory virus. Lower respiratory tract infections (bronchitis, bronchiolitis, and pneumonia) were far more common than upper respiratory tract (rhinitis, pharyngitis, and laryngitis) infections, 75 versus 25%, respectively. Over half of the infections were due to OC43-like strains. Approximately 20% were due to 229E-like strains and approximately 20% were due to NL63-strains. Coronavirus infections in the first year of life were associated predominantly with OC43-like strains. HCoV was identified in 5.4% of specimens from 279 hospitalized adult patients with lower respiratory tract infections. 239, 240 The most frequently identified isolates were HCoV-OC43 in 12, followed by HCoV-229E in 7, HCoV-NL63 in 6, and HCoV-HKU1 in 4 specimens. Many patients had highrisk underlying conditions. In several recent studies evaluating multiplex PCR assays, HCoVs were detected in 3 to 8% of hospitalized children younger than 5 years with acute respiratory illnesses. [241] [242] [243] Patients with SARS present with fever, cough, and/or myalgias. Dyspnea and hypoxemia were noted during the second week of illness. Rapidly progressive respiratory failure then occurred in a subset of patients. Patients appeared to be contagious after lower respiratory tract signs were observed. 244, 245 Nonspecific presenting symptoms are common in MERS-CoV-infected patients. Fever, chills, and sore throat are frequently reported. 246 Respiratory tract symptoms are also quite common. Within a few days of symptoms, respiratory failure can develop. Chest radiographic findings progress from a unilateral focal lesion to extensive multifocal or bilateral involvement, but are not specific to MERS-CoV infections. 247, 248 The most common CT findings are bilateral, often basilar, airspace involvement. Cavitation has not been reported. Late CT findings in recovered patients may include fibrotic changes and organizing pneumonia. Acute renal failure has often been observed during the second week of illness with MERS virus. This was also seen in a small percentage of SARS patients. Dialysis was often required. Other nonrespiratory tract involvement has been reported to include diarrhea (7-25% of patients), nausea, vomiting, pericarditis, and arrhythmias. 249 Complications of MERS include superinfection or coinfection, septic shock, and delirium. ICU care is often needed within 5 days of admission. The case-fatality rates have ranged from 25 to 76%. As more cases were identified, there have been more asymptomatic or mild cases identified. These have predominantly been in young, healthy women without significant comorbidities. There are no published randomized controlled trials of specific antiviral agents in the treatment of SARS or MERS. Supportive therapy is currently the only recommended plan. When renal failure occurs, renal dialysis is necessary. Mechanical ventilation in an ICU is often required. Several candidate antiviral agents have been identified and include IFNs, ribavirin, and cyclophilin inhibitors. [250] [251] [252] [253] [254] [255] [256] [257] Both in vitro cell culture experiments and animal studies have shown antiviral activity of these agents against MERS-CoV. However, very few human cases who received a combination of IFN-α2b, ribavirin, and corticosteroids survived. Prompt isolation of suspected SARS or MERS cases and contact tracing of case contacts are the keys to preventing nosocomial transmission. [258] [259] [260] Standard, contact, and droplet precautions should be used in all cases. Airborne precautions should be employed for aerosol-generating procedures, bronchoscopy, tracheostomy, and airway insertion. Vaccine design for SARS-CoV and MERS-CoV has focused on the development of chimeric spike glycoproteins containing neutralizing epitopes from multiple strains within or across subgroups. [261] [262] [263] [264] [265] [266] [267] Inclusion of nucleocapsid protein in chimeric vaccines could broaden the protective response. The S protein is the major determinant of protective immunity. Antibodies against S protein appeared to protect from SARS-CoV challenges in animal studies. N protein-specific immune response provides little protection and only crossreact within, but not between, subgroups. Thus, there are no approved vaccines for MERS or any of the CoVs. The use of convalescent-phase plasma or immune globulin with high titers of neutralizing antibody has not been evaluated in randomized controlled trials. 268 HRVs and HCoVs cause significant morbidity in immunocompetent people and in patients with underlying chronic or immunosuppressed medical conditions. Newer diagnostic tests have expanded our understanding of these respiratory viruses in clinical infections. These sensitive diagnostic tests have been used to detect new HRVs, such as HRV-C. Recent studies on the pathogenesis of HRVs and the host response to this group of viruses have provided insights into potential targets for therapeutic interventions. The recent outbreaks of SARS and MERS pose special problems in treatment and infection control. [269] [270] [271] Vaccine development for HCoVs and/or coronaviruses appears to be many years away. Tapparel This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Update on rhinovirus and coronavirus infections Human Respiratory Viral Infections Human coronavirus respiratory infections Human rhinoviruses children Sequence analysis of human rhinovirus aspirated from the nasopharynx of patients with relapsing-remitting MS New Vaccine Surveillance Network. A novel group of rhinoviruses is associated with asthma hospitalizations Rate of concurrent otitis media in upper respiratory tract infections with specific viruses Rhinovirus viremia in children with respiratory infections Pneumonia and pericarditis in a child with HRV-C infection: a case report Persistence of rhinovirus and enterovirus RNA after acute respiratory illness in children Picornavirus infections in children diagnosed by RT-PCR during longitudinal surveillance with weekly sampling: Association with symptomatic illness and effect of season Epidemiology of infections with rhinovirus types 43 and 55 in a group of university of Wisconsin student families Clinical severity and molecular typing of human rhinovirus C strains during a fall outbreak affecting hospitalized patients Phylogenetic analysis of rhinovirus isolates collected during successive epidemic seasons Human rhinovirus C: Age, season, and lower respiratory illness over the past 3 decades Community-wide, contemporaneous circulation of a broad spectrum of human rhinoviruses in healthy Australian preschool-aged children during a 12-month period Detection of multiple respiratory pathogens during primary respiratory infection: nasal swab versus nasopharyngeal aspirate using realtime polymerase chain reaction Comparison of the Luminex xTAG RVP Fast assay and the Idaho Technology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods Comparison of two multiplex methods for detection of respiratory viruses: FilmArray RP and xTAG RVP Comparison of the FilmArray Respiratory Panel and Prodesse real-time PCR assays for detection of respiratory pathogens Symptom severity patterns in experimental common colds and their usefulness in timing onset of illness in natural colds Incubation periods of experimental rhinovirus infection and illness Dual respiratory virus infections Detection of multiple respiratory viruses associated with mortality and severity of illness in children Does virus-bacteria coinfection increase the clinical severity of acute respiratory infection Prevalence of respiratory virus in symptomatic children in private physician office settings in five communities of the state of Veracruz Detection of viral and bacterial pathogens in hospitalized children with acute respiratory illnesses Detection of respiratory viruses in gargle specimens of healthy children Other respiratory viruses are important contributors to adult respiratory hospitalizations and mortality even during peak weeks of the influenza season Is virus coinfection a predictor of severity in children with viral respiratory infections? Viral aetiology of influenza-like illness in Belgium during the influenza A(H1N1) 2009 pandemic High burden of noninfluenza viruses in influenza-like illness in the early weeks of H1N1v epidemic in France The prevalance of respiratory viruses among healthcare workers serving pilgrims in Makkah during the 2009 influenza A (H1N1) pandemic Intense co-circulation of non-influenza respiratory viruses during the first wave of pandemic influenza pH1N1/2009: a cohort study in Reunion Island Respiratory viruses identified in an urban children's hospital emergency department during the 2009 influenza A(H1N1) pandemic The viral etiology of an influenza-like illness during the 2009 pandemic Influenza A/H1N1 2009 pandemic and respiratory virus infections Frequency of detection of upper respiratory tract viruses in patients tested for pandemic H1N1/09 viral infection Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza Viral aetiology influenza like illnesses in Santa Cruz Respiratory viruses associated with patients older than 50 years presenting with ILI in Senegal Viral etiology of influenza-like illnesses in Huizhou Genetic diversity and clinical impact of human rhinoviruses in hospitalized and outpatient children with acute respiratory infection, Argentina Influenza and other respiratory viruses involved in severe acute respiratory disease in northern Italy during the pandemic and postpandemic period Influenza and other respiratory virus infections in outpatients with medically attended acute respiratory infection during the 2011-12 influenza season Respiratory tract viral infections in inner-city asthmatic adults Respiratory viruses and exacerbations of asthma in adults Human rhinovirus group C infection in children with lower respiratory tract infection Experimental rhinovirus 16 infection causes variable airway obstruction in subjects with atopic asthma Rhinoviruses infect the lower airways Detection of rhinovirus RNA in lower airway cells during experimentally induced infection Rhinovirus stimulation of interleukin-8 in vivo and in vitro: role of NF-kappaB Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa Bdependent transcriptional activation Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma Role of deficient type III interferon-lambda production in asthma exacerbations Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children Rhinovirus-induced asthma exacerbations during childhood: the importance of understanding the atopic status of the host The role of early life viral bronchiolitis in the inception of asthma Rhinoviruses are a major cause of wheezing and hospitalization in children less than 2 years of age Detection of viruses identified recently in children with acute wheezing Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children Rhinovirus illnesses during infancy predict subsequent childhood wheezing Updates in the relationship between human rhinovirus and asthma Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life Rhinovirus wheezing illness and genetic risk of childhood-onset asthma Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study Viral etiology of acute exacerbations of COPD in Hong Kong Detection of multiple viral and bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a pilot prospective study Upper-respiratory viral infection, biomarkers, and COPD exacerbations influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression Importance of respiratory viruses in acute otitis media Acute otitis media and respiratory viruses Alterations of the eustachian tube, middle ear, and nose in rhinovirus infection Human rhinoviruses in otitis media with effusion Bacterial and respiratory viral interactions in the etiology of acute otitis media in HIVinfected and HIV-uninfected South African children Computed tomographic study of the common cold Middle ear abnormalities during natural rhinovirus colds in adults Presence of viral and bacterial pathogens in the nasopharynx of otitis-prone children. A prospective study Detection of rhinovirus in sinus brushings of patients with acute community-Seminars in Respiratory Unauthorized distribution is strictly prohibited. acquired sinusitis by reverse transcription-PCR Nose blowing propels nasal fluid into the paranasal sinuses Rhinovirus and coronavirus infection-associated hospitalizations among older adults Correlation of viral load of respiratory pathogens and co-infections with disease severity in children hospitalized for lower respiratory tract infection Viral pneumonia The role of respiratory viral infections among children hospitalized for community-acquired pneumonia in a developing country. Pediatr Viral infection in patients with severe pneumonia requiring intensive care unit admission Viral coinfection in children less than five years old with invasive pneumococcal disease Spectrum of respiratory viruses in children with community-acquired pneumonia Human rhinoviruses in severe respiratory disease in very low birth weight infants Impact of rhinoviruses on pediatric community-acquired pneumonia Incidence of respiratory virus-associated pneumonia in urban poor young children of Dhaka Acute viral lower respiratory tract infections in Cambodian children: clinical and epidemiologic characteristics Respiratory viruses in neonates hospitalized with acute lower respiratory tract infections Respiratory viruses from hospitalized children with severe pneumonia in the Philippines Human bocavirus and other respiratory viral infections in a 2-year cohort of hospitalized children Respiratory viral coinfections identified by a 10-plex real-time reverse-transcription polymerase chain reaction assay in patients hospitalized with severe acute respiratory illness-South Africa Human metapneumovirus associated with community-acquired pneumonia in children in Beijing Respiratory viral pathogens associated with lower respiratory tract disease among young children in the highlands of Papua New Guinea An investigation into the prevalence and outcome of patients admitted to a pediatric intensive care unit with viral respiratory tract infections in Cape Town Viral etiology of bronchiolitis among pediatric inpatients in northern Taiwan with emphasis on newly identified respiratory viruses Etiology of bronchiolitis in a hospitalized pediatric population: prospective multicenter study MARC-30 Investigators. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis Prevalence of human rhinovirus in children admitted to hospital with acute lower respiratory tract infections in Changsha Viral etiology of respiratory tract infections in children at the pediatric hospital in Ouagadougou Clinical evaluation of viral acute respiratory tract infections in children presenting to the emergency department of a tertiary referral hospital in the Netherlands Viral etiology of communityacquired pneumonia among adolescents and adults with mild or moderate severity and its relation to age and severity Etiology and clinical outcomes of acute respiratory virus infection in hospitalized adults Respiratory viral infections among hospitalized adults: experience of a single tertiary healthcare hospital Epidemiology of respiratory viruses in bronchoalveolar lavage samples in a tertiary hospital Clinical relevance of rhinovirus infections among adult hospitalized patients Respiratory virus is a real pathogen in immunocompetent community-acquired pneumonia: comparing to influenza like illness and volunteer controls Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults Pathogenicity of individual rhinovirus species during exacerbations of cystic fibrosis Effects of upper respiratory tract infections in patients with cystic fibrosis Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis Virus and cystic fibrosis: rhinoviruses are associated with exacerbations in adult patients Differential responses to rhinovirus-and influenza-associated pulmonary exacerbations in patients with cystic fibrosis Respiratory viruses and severe lower respiratory tract complications in hospitalized patients Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients Viral findings in adult hematological patients with neutropenia Frequency and clinical outcome of respiratory viral infections and mixed viral-bacterial infections in children with cancer, fever and neutropenia Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant Severe human rhinovirus outbreak associated with fatalities in a long-term care facility in Ontario Concurrent outbreaks of rhinovirus and respiratory syncytial virus in an intensive care nursery: epidemiology and associated risk factors An outbreak of human rhinovirus species C infections in a neonatal intensive care unit Human rhinovirus causes severe infection in preterm infants Rhinovirus outbreaks in long-term care facilities A rhinovirus outbreak among residents of a long-term care facility Echinacea in the prevention of induced rhinovirus colds: a meta-analysis Rhinovirus outbreak in a long term care facility for elderly persons associated with unusually high mortality Two outbreaks of severe respiratory disease in nursing homes associated with rhinovirus Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings Heated, humidified air for the common cold Antiviral therapy for enteroviruses and rhinoviruses Pleconaril Respiratory Infection Study Group. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials Echinacea purpurea for prevention of experimental rhinovirus colds Ineffectiveness of intranasal zinc gluconate for prevention of experimental rhinovirus colds The prophylactic and therapeutic effectiveness of zinc sulphate on common cold in children Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells Macrolide therapy in respiratory viral infections Short-and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode Virucidal hand treatments for prevention of rhinovirus infection Single treatment with ethanol hand rub is ineffective against human rhinovirus-hand washing with soap and water removes the virus efficiently Hand contamination with human rhinovirus in Bangladesh Prophylactic antibody treatment and intramuscular immunization reduce infectious human rhinovirus 16 load in the lower respiratory tract of challenged cotton rats Challenges in developing a cross-serotype rhinovirus vaccine Developing a vaccine for human rhinoviruses Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1 Human aminopeptidase N is a receptor for human coronavirus 229E A structural view of coronavirus-receptor interactions Receptor recognition mechanisms of coronaviruses: a decade of structural studies Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins HCoV-HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor Seminars in Respiratory Unauthorized distribution is strictly prohibited. determinant and employs HE protein as a receptor-destroying enzyme Molecular pathology of emerging coronavirus infections Systems approaches to Coronavirus pathogenesis Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice E2018-E2026 208 van den Brand JM, Smits SL, Haagmans BL. Pathogenesis of Middle East respiratory syndrome coronavirus SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon Immunogenicity and antigenicity of human coronaviruses 229E and OC43 Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease Association of viral and bacterial respiratory infection with exacerbations of wheezing in young asthmatic children The "common cold" in frail older persons: impact of rhinovirus and coronavirus in a senior daycare center Human coronavirus NL63 and 229E seroconversion in children Identification of a novel coronavirus in patients with severe acute respiratory syndrome Human coronavirus NL63 New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia Identification of a new human coronavirus Coronavirus HKU1 infection in the United States Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children The pediatric burden of human coronaviruses evaluated for twenty years Circulation of genetically distinct contemporary human coronavirus OC43 strains Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus Community case clusters of Middle East respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study CDC announces second imported case of Middle East Respiratory Syndrome (MERS) in the United States Centers for Disease Control and Prevention. CDC telebriefing: updates on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) investigation in the United States. Available at Lennette's Laboratory Diagnosis of Viral Infections Direct diagnosis of human respiratory coronaviruses 229E and OC43 by the polymerase chain reaction Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients Comprehensive detection and identification of human coronaviruses, including the SARSassociated coronavirus, with a single RT-PCR assay Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations Specific serology for emerging human coronaviruses by protein microarray Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome A safe and convenient pseudovirusbased inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV Evidence for camel-tohuman transmission of MERS coronavirus Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients Detection of human coronavirus NL63 in young children with bronchiolitis Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalised children in France Clinical manifestations of human coronavirus NL63 infection in children in Taiwan The severe acute respiratory syndrome A novel coronavirus associated with severe acute respiratory syndrome The emergence of the Middle East respiratory syndrome coronavirus Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings Severe acute respiratory syndrome: 11 years later-a radiology perspective Middle East respiratory syndrome (MERS): a new zoonotic viral pneumonia The management of coronavirus infections with particular reference to SARS Cyclophilins as modulators of viral replication Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Middle East respiratory syndrome coronavirus: epidemiology and disease control measures A decade after SARS: strategies for controlling emerging coronaviruses Middle East respiratory syndrome coronavirus: implications for health care facilities The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies T cell-mediated immune response to respiratory coronaviruses Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragmentsthe importance of immunofocusing in subunit vaccine design Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines Receptor-binding domainbased subunit vaccines against MERS-CoV Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Clinical management and infection control of SARS: lessons learned Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses Middle East respiratory syndrome: what clinicians need to know